Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Arch Resources, Inc. (ARCH)

Bituminous Coal & Lignite Surface Mining

https://www.archrsc.com

Arch Resources Inc is a producer of metallurgical and coking coal. The company sells its coal to power plants, steel mills, and industrial facilities. Its operating segment includes Metallurgical (MET) and Thermal. It generates maximum revenue from the Metallurgical (MET) segment. Geographically, it derives a majority of its revenue from Asia.

CITY PLACE ONE STE 300, ARCH MINERAL CORP
ST LOUIS, MO

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/11/1988

Market Cap

2,291,848,685

Shares Outstanding

18,370,000

Weighted SO

18,369,460

Total Employees

N/A

Upcoming Earnings

07/25/2024

Similar Tickers

HCC --.--%

METC --.--%

SXC --.--%

AREC --.--%

AMR --.--%

Beta

0.6520

Last Div

4.1400

Range

120.52-187.6

Chg

3.2000

Avg Vol

335062

Mkt Cap

2291848685

Exch

NYSE

Country

US

Phone

314 994 2700

DCF Diff

-214.5821

DCF

340.4121

Div Yield

0.0620

P/S

0.8163

EV Multiple

4.8050

P/FV

1.5811

Div Yield %

6.2022

P/E

8.8426

PEG

0.5235

Payout

0.6091

Current Ratio

2.5381

Quick Ratio

1.7747

Cash Ratio

0.7479

DSO

32.2305

DIO

37.5365

Op Cycle

69.7670

DPO

28.0247

CCC

41.7423

Gross Margin

0.1346

Op Margin

0.0988

Pretax Margin

0.1078

Net Margin

0.0924

Eff Tax Rate

0.1427

ROA

0.1076

ROE

0.1791

ROCE

0.1331

NI/EBT

0.8573

EBT/EBIT

1.0910

EBIT/Rev

0.0988

Debt Ratio

0.0568

D/E

0.0943

LT Debt/Cap

0.0655

Total Debt/Cap

0.0862

Int Coverage

36.7736

CF/Debt

3.6536

Equity Multi

1.6618

Rec Turnover

11.3247

Pay Turnover

13.0242

Inv Turnover

9.7239

FA Turnover

2.2408

Asset Turnover

1.1647

OCF/Share

27.6252

FCF/Share

17.0270

Cash/Share

15.4937

OCF/Sales

0.1781

FCF/OCF

0.6164

CF Coverage

3.6536

ST Coverage

14.2140

CapEx Coverage

2.6066

Div&CapEx Cov

1.4293

P/BV

1.5811

P/B

1.5811

P/S

0.8163

P/E

8.8426

P/FCF

7.4378

P/OCF

4.5875

P/CF

4.5875

PEG

0.5235

P/S

0.8163

EV Multiple

4.8050

P/FV

1.5811

DPS

7.8600

Latest Headlines (EST)

GlobeNewswire Inc. Nov 22, 22:45 $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MKFG, CFB, and ARCH Zacks Investment Research Jan 18, 04:15 Zacks.com featured highlights NRG Energy, Suzano, Arch Resources, Cboe Global Markets and Arch Capital GlobeNewswire Inc. Jan 10, 07:26 Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury GlobeNewswire Inc. Jan 03, 07:33 Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury Zacks Investment Research Dec 28, 23:01 2 Energy Stocks to Buy with Robust Bottom Lines Going into 2024 Zacks Investment Research Dec 28, 23:01 2 Energy Stocks to Buy with Robust Bottom Lines Going into 2024 Zacks Investment Research Dec 28, 23:01 2 Energy Stocks to Buy with Robust Bottom Lines Going into 2024 Zacks Investment Research Dec 28, 23:01 2 Energy Stocks to Buy with Robust Bottom Lines Going into 2024 Zacks Investment Research Dec 28, 23:01 2 Energy Stocks to Buy with Robust Bottom Lines Going into 2024 GlobeNewswire Inc. Dec 21, 07:30 Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide GlobeNewswire Inc. Dec 13, 07:25 Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide Benzinga Nov 17, 11:00 5 Analysts Have This to Say About Arch Resources

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
1.11 05/31/2024 04/25/2024 05/31/2024 06/14/2024
1.65 02/28/2024 02/15/2024 02/29/2024 03/15/2024
1.13 11/29/2023 10/26/2023 11/30/2023 12/15/2023
3.97 08/30/2023 07/27/2023 08/31/2023 09/15/2023
2.45 05/30/2023 04/27/2023 05/31/2023 06/15/2023
3.11 02/27/2023 02/16/2023 02/28/2023 03/15/2023
10.75 11/29/2022 10/27/2022 11/30/2022 12/15/2022
6.00 08/30/2022 07/28/2022 08/31/2022 09/15/2022
8.11 05/27/2022 04/22/2022 05/31/2022 06/15/2022
0.25 02/25/2022 02/15/2022 02/28/2022 03/15/2022
0.25 11/29/2021 10/26/2021 11/30/2021 12/15/2021
0.50 03/02/2020 02/06/2020 03/03/2020 03/13/2020
0.45 11/27/2019 10/22/2019 11/29/2019 12/13/2019
0.45 08/29/2019 07/23/2019 08/30/2019 09/13/2019
0.45 05/30/2019 04/23/2019 05/31/2019 06/14/2019
0.45 03/04/2019 02/14/2019 03/05/2019 03/15/2019
0.40 11/29/2018 10/23/2018 11/30/2018 12/14/2018
0.40 08/30/2018 07/31/2018 08/31/2018 09/14/2018
0.40 05/30/2018 04/26/2018 05/31/2018 06/15/2018
0.40 03/02/2018 02/13/2018 03/05/2018 03/15/2018
0.35 11/29/2017 10/30/2017 11/30/2017 12/15/2017
0.35 08/29/2017 07/28/2017 08/31/2017 09/15/2017
0.35 05/26/2017 05/02/2017 05/31/2017 06/15/2017